Compare INO & NTIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INO | NTIC |
|---|---|---|
| Founded | 1979 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 81.9M |
| IPO Year | 1999 | 1996 |
| Metric | INO | NTIC |
|---|---|---|
| Price | $0.73 | $8.02 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 7.8K |
| Earning Date | 05-08-2026 | 04-09-2026 |
| Dividend Yield | N/A | ★ 0.49% |
| EPS Growth | ★ 54.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $42,220,086.00 | ★ $84,234,474.00 |
| Revenue This Year | $20,156.19 | $12.49 |
| Revenue Next Year | $421.95 | $7.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.37 | N/A |
| 52 Week Low | $0.56 | $7.16 |
| 52 Week High | $2.86 | $10.03 |
| Indicator | INO | NTIC |
|---|---|---|
| Relative Strength Index (RSI) | 33.01 | 44.87 |
| Support Level | $0.56 | $7.86 |
| Resistance Level | $1.24 | $8.03 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 31.29 | 17.46 |
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.